Clinical Trials Logo

Filter by:
  • None
  • Page [1]
NCT ID: NCT02428920 Completed - Health Behavior Clinical Trials

Grenada Heart Project - Community Health Action to Encourage Healthy Behaviors

GHP CHANGE
Start date: July 2014
Phase: Phase 3
Study type: Interventional

The Grenada Heart Project (GHP) conducted an observational study within a randomly selected adult sample of Grenadians in 2008-2009. The aim of the study was to assess the clinical, biological and psychosocial determinants of the cardiovascular health in Grenada, in order to develop and implement a nationwide cardiovascular health promotion program. The sample of 2,827 adults was randomly selected from the national electronic voter list. The main outcome measures were self-reported cardiovascular disease and behavioral risk factors, anthropometric measures, blood pressure (BP), point-of-care testing for glucose and lipids, and ankle-brachial index. Analysis of the data revealed prevalence rates of obesity, hypertension and diabetes significantly exceeding those seen in the U.S. Since the completion of this assessment, an additional effort has contributed significantly to the current project. A parallel community health-promotion project was carried out in Cardona, Spain called the "Cardona Integral Fifty-Fifty" project with 80 subjects. The preliminary results of the Cardona study have a shown that peer motivation may significantly improve healthy behaviors and thus modify cardiovascular risk. The GHP CHANGE community -based intervention aims to promote positive behaviors and focus more on what creates health, rather than what prevents sickness. It is built on the foundations of social support, assessing whether people going through similar challenges will support each other, work together to identify and address barriers to success, and motivate each other to move forward. In this program we test for the impact of promotion of healthy lifestyle behaviors through peer motivation on blood pressure, physical activity, eating behavior, weight, and smoking.

NCT ID: NCT01832012 Completed - Clinical trials for Cardiopulmonary Resuscitation Skill Retention in Medical Students

Basic Life Support Cardiopulmonary Resuscitation Refresher in MS2 at St George's University

Start date: July 2012
Phase: N/A
Study type: Interventional

175 second year medical students were assessed on their BLS CPR skill retention after an approximate one year after taking the initial certification class, and the investigators assessed which type of refresher course would be most effective in improving the students' CPR skills. Group 2 had no refresher, Group 3 had a multimedia refresher, and Group 4 had the same multimedia refresher plus hands on practice on a Laerdal BLS manikin. The investigators hypothesized that Group 4 would perform CPR skills with the highest competency compared to the other two groups.

NCT ID: NCT01042769 Completed - Clinical trials for Diabetes Mellitus Type 2

A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus

Start date: February 2010
Phase: Phase 3
Study type: Interventional

This double-blind, parallel, two-arm study will evaluate the potential to reduce cardiovascular risk, the tolerability and long-term safety profile of aleglitazar compared to placebo on top of standard care in patients with recent acute coronary syndrome (ACS) and type 2 diabetes mellitus. Patients will be randomized to receive either aleglitazar or placebo once daily as oral doses. The study will last until at least 950 events occur, but time on study treatment will be for at least 2.5 years.

NCT ID: NCT00658515 Completed - Clinical trials for Coronary Heart Disease

A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome

Start date: April 2008
Phase: Phase 3
Study type: Interventional

This study will evaluate the potential of RO4607381 to reduce cardiovascular morbidity and mortality in stable coronary heart disease patients with recent Acute Coronary Syndrome (ACS) and evaluate the long term safety profile of the drug. Eligible patients in stable condition will be randomized to receive either RO4607381 600mg po or placebo po, daily, together with a background of standard medication for ACS (including aspirin, antihypertensives and statins). The anticipated time on study treatment is 2+ years, and the target sample size is 15,600 individuals.